{
  "items": "50",
  "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
  "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
  "feed": [
    {
      "title": "Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine",
      "url": "https://www.vcstar.com/press-release/story/15025/aspire-biopharma-welcomes-elite-ultra-runner-ashley-paulson-as-global-brand-ambassador-for-buzz-bombr-caffeine/",
      "time_published": "20251221T180938",
      "authors": [
        "Aspire Biopharma Holdings",
        "Inc."
      ],
      "summary": "Aspire Biopharma Holdings, Inc. has announced that elite ultra-runner and Ironman champion Ashley Paulson will be the global brand ambassador for its sublingual caffeine product, BUZZ BOMB\u2122. Paulson, known for her extraordinary endurance achievements and \"funsistency\" philosophy, will use BUZZ BOMB\u2122 to support her rigorous training and lifestyle, advocating for its rapid, jitter-free energy delivery. This partnership aims to expand Aspire Biopharma's reach into the high-performance athletics market through authentic engagement and scientific innovation.",
      "banner_image": "https://app.accessnewswire.com/imagelibrary/d6026dd3-296f-4622-a1dd-d32404e78e03/1118935/image.jpeg",
      "source": "Ventura County Star",
      "category_within_source": "General",
      "source_domain": "Ventura County Star",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.915579"
        },
        {
          "topic": "finance",
          "relevance_score": "0.745648"
        }
      ],
      "overall_sentiment_score": 0.458674,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.472200",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Aspire Biopharma welcomes Ashley Paulson as Brand Ambassador",
      "url": "https://www.comunicaffe.com/aspire-biopharma-welcomes-elite-ultra-runner-ashley-paulson-as-global-brand-ambassador-for-buzz-bombr-caffeine/",
      "time_published": "20251219T120908",
      "authors": [],
      "summary": "Aspire Biopharma has announced ultra-runner and Ironman champion Ashley Paulson as the global brand ambassador for its BUZZ BOMB\u2122 caffeine product. Paulson, known for her extraordinary endurance achievements and \"funsistency\" philosophy, will promote the sublingual caffeine product, which offers rapid absorption for instant energy without digestive upset. Interim CEO Kraig Higginson emphasized that Paulson embodies the brand's high energy and relies on their technology to perform at the highest level.",
      "banner_image": "https://www.comunicaffe.com/wp-content/uploads/2025/12/Aspire-Biopharma.jpg",
      "source": "Comunicaffe International",
      "category_within_source": "General",
      "source_domain": "Comunicaffe International",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.936753"
        },
        {
          "topic": "retail_wholesale",
          "relevance_score": "0.719907"
        },
        {
          "topic": "finance",
          "relevance_score": "0.604815"
        }
      ],
      "overall_sentiment_score": 0.401297,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "0.931450",
          "ticker_sentiment_score": "0.439396",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine",
      "url": "https://www.heraldmailmedia.com/press-release/story/38669/aspire-biopharma-welcomes-elite-ultra-runner-ashley-paulson-as-global-brand-ambassador-for-buzz-bombr-caffeine/",
      "time_published": "20251218T200944",
      "authors": [
        "Aspire Biopharma Holdings",
        "Inc."
      ],
      "summary": "Aspire Biopharma Holdings, Inc. has announced that professional ultra-marathoner and Ironman champion Ashley Paulson will be the official Brand Ambassador for their sublingual caffeine product, BUZZ BOMB\u2122. Paulson, known for her extraordinary endurance achievements including two Badwater 135 titles, embodies the product's focus on rapid and sustained energy without digestive upset. This partnership aims to expand Aspire Biopharma's reach into the high-performance athletics market by leveraging Paulson's authentic appeal and extensive social media following.",
      "banner_image": "https://app.accessnewswire.com/imagelibrary/d6026dd3-296f-4622-a1dd-d32404e78e03/1118935/image.jpeg",
      "source": "The Herald-Mail",
      "category_within_source": "General",
      "source_domain": "The Herald-Mail",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.916030"
        }
      ],
      "overall_sentiment_score": 0.405912,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.441769",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine",
      "url": "https://www.phillyburbs.com/press-release/story/16553/aspire-biopharma-welcomes-elite-ultra-runner-ashley-paulson-as-global-brand-ambassador-for-buzz-bombr-caffeine/",
      "time_published": "20251218T200912",
      "authors": [
        "Aspire Biopharma Holdings",
        "Inc."
      ],
      "summary": "Aspire Biopharma Holdings, Inc. announced that ultra-marathoner and Ironman champion Ashley Paulson has joined as the official Brand Ambassador for their sublingual caffeine product, BUZZ BOMB\u2122. Paulson, known for her endurance and \"funsistency\" philosophy, will use BUZZ BOMB\u2122 for training and racing, highlighting its rapid absorption and effectiveness without jitters or stomach upset. This partnership aims to expand Aspire Biopharma's reach into the high-performance athletics market through Paulson's authentic endorsement and extensive social media presence.",
      "banner_image": "https://app.accessnewswire.com/imagelibrary/d6026dd3-296f-4622-a1dd-d32404e78e03/1118935/image.jpeg",
      "source": "PhillyBurbs",
      "category_within_source": "General",
      "source_domain": "PhillyBurbs",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.929790"
        }
      ],
      "overall_sentiment_score": 0.477979,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.462304",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine",
      "url": "https://fox59.com/business/press-releases/accesswire/1118935/aspire-biopharma-welcomes-elite-ultra-runner-ashley-paulson-as-global-brand-ambassador-for-buzz-bombr-caffeine",
      "time_published": "20251218T200908",
      "authors": [
        "NULL"
      ],
      "summary": "Aspire Biopharma Holdings, Inc. has announced that professional ultra-marathoner and Ironman champion Ashley Paulson will be the official Brand Ambassador for their sublingual caffeine product, BUZZ BOMB\u2122. Paulson, known for her exceptional endurance achievements including winning the Badwater 135, will utilize BUZZ BOMB\u2122 for her training and recovery due to its rapid, jitters-free energy delivery. This partnership aims to expand Aspire Biopharma's reach into the high-performance athletics market, leveraging Paulson's extensive social media following and authentic approach to fitness.",
      "banner_image": "https://app.accessnewswire.com/imagelibrary/d6026dd3-296f-4622-a1dd-d32404e78e03/1118935/image.jpeg",
      "source": "Fox 59",
      "category_within_source": "General",
      "source_domain": "Fox 59",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.945600"
        },
        {
          "topic": "finance",
          "relevance_score": "0.727419"
        }
      ],
      "overall_sentiment_score": 0.443924,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.405269",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine",
      "url": "https://www.dispatch.com/press-release/story/132934/aspire-biopharma-welcomes-elite-ultra-runner-ashley-paulson-as-global-brand-ambassador-for-buzz-bombr-caffeine/",
      "time_published": "20251218T190939",
      "authors": [
        "Aspire Biopharma Holdings",
        "Inc."
      ],
      "summary": "Aspire Biopharma Holdings, Inc. announced that elite ultra-marathoner and Ironman champion Ashley Paulson has been named the global brand ambassador for BUZZ BOMB\u2122, its sublingual caffeine product. Paulson, known for her extraordinary endurance achievements and \"funsistency\" philosophy, will promote BUZZ BOMB\u2122 through her extensive social media presence and at major endurance events. The partnership highlights BUZZ BOMB\u2122's rapid, jitters-free energy delivery, catering to athletes and individuals needing instant cognitive boosts.",
      "banner_image": "https://app.accessnewswire.com/imagelibrary/d6026dd3-296f-4622-a1dd-d32404e78e03/1118935/image.jpeg",
      "source": "The Columbus Dispatch",
      "category_within_source": "General",
      "source_domain": "The Columbus Dispatch",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.911423"
        },
        {
          "topic": "finance",
          "relevance_score": "0.745520"
        }
      ],
      "overall_sentiment_score": 0.803363,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.802711",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine",
      "url": "https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/aspire-biopharma-welcomes-elite-ultra-runner-ashley-paulson-as-global-1118935",
      "time_published": "20251218T130922",
      "authors": [
        "NULL"
      ],
      "summary": "Aspire Biopharma Holdings, Inc. has announced elite ultra-runner and Ironman champion Ashley Paulson as the new Global Brand Ambassador for BUZZ BOMB(R) Caffeine, its sublingual caffeine product. Paulson, known for her extraordinary endurance achievements and \"funsistency\" philosophy, will use BUZZ BOMB to support her training and recovery needs, leveraging its rapid, jitters-free energy delivery. This partnership aims to expand Aspire Biopharma's reach into high-performance athletics and fitness markets through Paulson's authentic engagement and extensive social media presence.",
      "banner_image": "https://app.accessnewswire.com/imagelibrary/d6026dd3-296f-4622-a1dd-d32404e78e03/1118935/image.jpeg",
      "source": "ACCESS Newswire",
      "category_within_source": "General",
      "source_domain": "ACCESS Newswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.914637"
        }
      ],
      "overall_sentiment_score": 0.489334,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.498812",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements",
      "url": "https://www.cjonline.com/press-release/story/10156/aspire-biopharma-granted-extension-by-nasdaq-hearing-panel-to-regain-compliance-with-continued-listing-requirements/",
      "time_published": "20251215T200944",
      "authors": [
        "Aspire Biopharma Holdings",
        "Inc."
      ],
      "summary": "Aspire Biopharma has been granted an extension by the Nasdaq Hearing Panel to comply with continued listing requirements, specifically the Bid Price Rule by January 30, 2026, and the Equity Rule by February 17, 2026. The company will transfer its common stock listing from the Nasdaq Global Select Market to the Nasdaq Capital Market, effective December 15, 2025, and believes this extension will allow them to regain compliance through recapitalization efforts.",
      "banner_image": "NULL",
      "source": "The Topeka Capital-Journal",
      "category_within_source": "General",
      "source_domain": "The Topeka Capital-Journal",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.941800"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.828697"
        },
        {
          "topic": "finance",
          "relevance_score": "0.749749"
        }
      ],
      "overall_sentiment_score": 0.252476,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.253431",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Aspire Biopharma Provides Q3 2025 Business Update",
      "url": "https://www.jacksonville.com/press-release/story/975991/aspire-biopharma-provides-q3-2025-business-update/",
      "time_published": "20251215T200922",
      "authors": [
        "Aspire Biopharma Holdings",
        "Inc."
      ],
      "summary": "Aspire Biopharma reported significant progress in Q3 2025, including expanding its scientific team, submitting a Pre-IND meeting request to the FDA for its sublingual aspirin, and participating in the CPHI Frankfurt trade show. The company also filed an omnibus patent application for its sublingual delivery technology and launched its BUZZ BOMB\u2122 caffeine product, increasing production capacity due to demand. Aspire Biopharma forecasts an NDA submission for its sublingual aspirin in H1 2026 and initiation of clinical studies for sublingual ED medication by mid-2026.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1112550",
      "source": "The Florida Times-Union",
      "category_within_source": "General",
      "source_domain": "The Florida Times-Union",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.906674"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.816224"
        }
      ],
      "overall_sentiment_score": 0.430756,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.415928",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements",
      "url": "https://www.pjstar.com/press-release/story/16058/aspire-biopharma-granted-extension-by-nasdaq-hearing-panel-to-regain-compliance-with-continued-listing-requirements/",
      "time_published": "20251214T210842",
      "authors": [
        "Aspire Biopharma Holdings",
        "Inc."
      ],
      "summary": "Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) has received an extension from the Nasdaq Listing Qualifications Panel to regain compliance with continued listing requirements, allowing its common stock to continue trading on The Nasdaq Capital Market. The company must meet the Bid Price Rule by January 30, 2026, and the Equity Rule by February 17, 2026. Aspire's Interim CEO, Kraig Higginson, expressed confidence in the company's plan to recapitalize and address the deficiencies within the given timeframe.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1117128",
      "source": "Peoria Journal Star",
      "category_within_source": "General",
      "source_domain": "Peoria Journal Star",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.941216"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.818299"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.709433"
        }
      ],
      "overall_sentiment_score": 0.131912,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.138799",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements",
      "url": "https://www.redding.com/press-release/story/11474/aspire-biopharma-granted-extension-by-nasdaq-hearing-panel-to-regain-compliance-with-continued-listing-requirements/",
      "time_published": "20251214T190939",
      "authors": [
        "Aspire Biopharma Holdings",
        "Inc."
      ],
      "summary": "Aspire Biopharma has received an extension from the Nasdaq Hearings Panel to regain compliance with continued listing requirements, allowing it to remain listed on the Nasdaq Capital Market. The company must meet specific conditions related to its bid price and equity rule by January 30, 2026, and February 17, 2026, respectively. Interim CEO Kraig Higginson expressed confidence in their plan to recapitalize the balance sheet and deliver long-term shareholder value.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1117128",
      "source": "Record Searchlight",
      "category_within_source": "General",
      "source_domain": "Record Searchlight",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.919031"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.800056"
        },
        {
          "topic": "finance",
          "relevance_score": "0.703967"
        }
      ],
      "overall_sentiment_score": 0.344542,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.303631",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Aspire Biopharma Provides Q3 2025 Business Update",
      "url": "https://www.enterprisenews.com/press-release/story/59508/aspire-biopharma-provides-q3-2025-business-update/",
      "time_published": "20251214T190939",
      "authors": [
        "Aspire Biopharma Holdings",
        "Inc."
      ],
      "summary": "Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) has provided a Q3 2025 business update, highlighting significant milestones including the expansion of its scientific team, positive FDA response for its lead product candidate, and increased production capacity for its BUZZ BOMB\u2122 caffeine product. The company also unveiled its new e-commerce solution for BUZZ BOMB\u2122 and shared anticipated milestones for its sublingual high-dose aspirin and ED medication programs. Interim CEO Kraig Higginson emphasized the blueprint for future value creation through clinically proven technology and commercial execution.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1112550",
      "source": "Enterprise News",
      "category_within_source": "General",
      "source_domain": "Enterprise News",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.918052"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.948460"
        }
      ],
      "overall_sentiment_score": 0.85343,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.860233",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements",
      "url": "https://www.patriotledger.com/press-release/story/12905/aspire-biopharma-granted-extension-by-nasdaq-hearing-panel-to-regain-compliance-with-continued-listing-requirements/",
      "time_published": "20251212T210842",
      "authors": [
        "Aspire Biopharma Holdings",
        "Inc."
      ],
      "summary": "Aspire Biopharma Holdings, Inc. received an extension from the Nasdaq Hearings Panel to regain compliance with continued listing requirements, with deadlines of January 30, 2026, for the Bid Price Rule and February 17, 2026, for the Equity Rule. Their common stock will transfer to the Nasdaq Capital Market but continue trading under the symbol ASBP. Interim CEO Kraig Higginson stated confidence in curing deficiencies and recapitalizing the balance sheet to deliver long-term shareholder value.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1117128",
      "source": "The Patriot Ledger",
      "category_within_source": "General",
      "source_domain": "The Patriot Ledger",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.944107"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.812076"
        }
      ],
      "overall_sentiment_score": 0.237624,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.206337",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Aspire Biopharma Provides Q3 2025 Business Update",
      "url": "https://www.southcoasttoday.com/press-release/story/14335/aspire-biopharma-provides-q3-2025-business-update/",
      "time_published": "20251212T210842",
      "authors": [
        "Aspire Biopharma Holdings",
        "Inc."
      ],
      "summary": "Aspire Biopharma Holdings, Inc. (Nasdaq: ASBP) released its Q3 2025 business update, highlighting significant progress in its sublingual drug delivery technology. Key achievements include expanding its scientific team, submitting a Pre-IND meeting request to the FDA for its sublingual aspirin, and successfully launching its BUZZ BOMB\u2122 caffeine product. The company anticipates an NDA submission for sublingual aspirin in H1 2026 and aims to disrupt multi-billion-dollar markets with its innovative technology.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1112550",
      "source": "SouthCoastToday.com",
      "category_within_source": "General",
      "source_domain": "SouthCoastToday.com",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.918702"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.923780"
        }
      ],
      "overall_sentiment_score": 0.413152,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.406891",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements",
      "url": "https://www.ydr.com/press-release/story/11435/aspire-biopharma-granted-extension-by-nasdaq-hearing-panel-to-regain-compliance-with-continued-listing-requirements/",
      "time_published": "20251212T200922",
      "authors": [
        "Aspire Biopharma Holdings",
        "Inc."
      ],
      "summary": "Aspire Biopharma Holdings, Inc. announced that it received an extension from the Nasdaq Listing Qualifications Panel to maintain its listing on The Nasdaq Stock Market. The company must meet specific conditions by January 30, 2026, and February 17, 2026, including compliance with bid price and equity rules, and will transfer its common stock listing to The Nasdaq Capital Market. Aspire Biopharma's Interim CEO, Kraig Higginson, expressed confidence in the company's plan to regain compliance and recapitalize for long-term shareholder value.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1117128",
      "source": "York Daily Record",
      "category_within_source": "General",
      "source_domain": "York Daily Record",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.905038"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.845015"
        },
        {
          "topic": "finance",
          "relevance_score": "0.710625"
        }
      ],
      "overall_sentiment_score": 0.236162,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.230704",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements",
      "url": "https://www.oklahoman.com/press-release/story/121566/aspire-biopharma-granted-extension-by-nasdaq-hearing-panel-to-regain-compliance-with-continued-listing-requirements/",
      "time_published": "20251212T200922",
      "authors": [
        "Aspire Biopharma Holdings",
        "Inc."
      ],
      "summary": "Aspire Biopharma Holdings, Inc. received an extension from the Nasdaq Hearing Panel to continue its listing, subject to meeting specific compliance conditions by early 2026. The company's common stock will transfer to The Nasdaq Capital Market and leadership expressed confidence in their plan to regain compliance and recapitalize.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1117128",
      "source": "The Oklahoman",
      "category_within_source": "General",
      "source_domain": "The Oklahoman",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.949521"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.809560"
        }
      ],
      "overall_sentiment_score": 0.218461,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.219095",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Aspire Biopharma gets Nasdaq extension to meet listing requirements By Investing.com",
      "url": "https://ca.investing.com/news/company-news/aspire-biopharma-gets-nasdaq-extension-to-meet-listing-requirements-93CH-4363826",
      "time_published": "20251212T051000",
      "authors": [
        "Investing.com"
      ],
      "summary": "Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) has received an extension from Nasdaq to maintain its listing, despite its stock plummeting 99% over the past year. The company's common stock will transfer to the Nasdaq Capital Market, and it must meet minimum bid price and equity requirements by January 30, 2026, and February 17, 2026, respectively. CEO Kraig Higginson stated this extension will allow Aspire to regain compliance as it continues to develop its sublingual drug delivery technology.",
      "banner_image": "https://i-invdn-com.investing.com/news/World_News_9_800x533_L_1420026261.jpg",
      "source": "Investing.com Canada",
      "category_within_source": "General",
      "source_domain": "Investing.com Canada",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.949937"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.832885"
        }
      ],
      "overall_sentiment_score": 0.007931,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.016429",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements",
      "url": "https://www.wric.com/business/press-releases/accesswire/1117128/aspire-biopharma-granted-extension-by-nasdaq-hearing-panel-to-regain-compliance-with-continued-listing-requirements",
      "time_published": "20251212T050000",
      "authors": [],
      "summary": "Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) has been granted an extension by the Nasdaq Hearings Panel to regain compliance with continued listing requirements, specifically the Bid Price Rule by January 30, 2026, and the Equity Rule by February 17, 2026. The company's common stock will transfer from the Nasdaq Global Select Market to the Nasdaq Capital Market on December 15, 2025, continuing to trade under the symbol \"ASBP\" without affecting trading. Interim CEO Kraig Higginson stated optimism about meeting compliance deadlines through a plan to recapitalize the balance sheet and deliver long-term shareholder value.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1117128",
      "source": "WRIC ABC 8News",
      "category_within_source": "General",
      "source_domain": "WRIC ABC 8News",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.905222"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.834800"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.705465"
        }
      ],
      "overall_sentiment_score": 0.185043,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.189434",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Aspire Biopharma Provides Q3 2025 Business Update",
      "url": "https://www.news-journalonline.com/press-release/story/15852/aspire-biopharma-provides-q3-2025-business-update/",
      "time_published": "20251211T220837",
      "authors": [
        "Aspire Biopharma Holdings",
        "Inc."
      ],
      "summary": "Aspire Biopharma Holdings, Inc. (Nasdaq: ASBP) has provided a business update for Q3 2025, highlighting significant advancements in its sublingual drug delivery technology. Key achievements include expanding its scientific team, submitting a Pre-IND meeting request to the FDA for its sublingual aspirin formulation, and launching an influencer marketing campaign for its BUZZ BOMB\u2122 caffeine product. The company anticipates filing additional patents and targeting an NDA submission for sublingual aspirin in H1 2026.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1112550",
      "source": "Daytona Beach News-Journal",
      "category_within_source": "General",
      "source_domain": "Daytona Beach News-Journal",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.936422"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.919509"
        }
      ],
      "overall_sentiment_score": 0.475633,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.469381",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)",
      "url": "https://www.pnj.com/press-release/story/14766/aspire-biopharma-submits-pre-ind-meeting-request-and-briefing-package-to-us-fda-for-sublingual-aspirin-product-for-treatment-of-suspected-acute-myocardial-infarction-heart-attack/",
      "time_published": "20251208T220937",
      "authors": [
        "Aspire Biopharma Holdings",
        "Inc."
      ],
      "summary": "Aspire Biopharma has submitted a Pre-IND meeting request and briefing package to the U.S. FDA for its sublingual aspirin product, designed for rapid treatment of suspected acute myocardial infarction. Clinical data shows the sublingual formulation inhibits platelet aggregation significantly faster than chewed aspirin, offering a potentially life-saving advantage. The company plans to pursue a 505(b)(2) regulatory pathway, leveraging existing aspirin data to expedite development.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1112553",
      "source": "Pensacola News Journal",
      "category_within_source": "General",
      "source_domain": "Pensacola News Journal",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.902760"
        },
        {
          "topic": "finance",
          "relevance_score": "0.613726"
        }
      ],
      "overall_sentiment_score": 0.492556,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.492094",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Aspire Biopharma Provides Q3 2025 Business Update",
      "url": "https://www.dnj.com/press-release/story/34372/aspire-biopharma-provides-q3-2025-business-update/",
      "time_published": "20251207T190939",
      "authors": [
        "Aspire Biopharma Holdings",
        "Inc."
      ],
      "summary": "Aspire Biopharma has released a Q3 2025 business update, highlighting significant progress in its sublingual drug delivery technology. Key achievements include FDA engagement for its sublingual aspirin program, expansion of its scientific team, and successful commercial launch and production scaling of its BUZZ BOMB\u2122 caffeine product. The company anticipates further milestones, including an NDA submission for sublingual aspirin in H1 2026.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1112550",
      "source": "The Daily News Journal",
      "category_within_source": "General",
      "source_domain": "The Daily News Journal",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.919137"
        }
      ],
      "overall_sentiment_score": 0.40109,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.430137",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Aspire Biopharma Provides Q3 2025 Business Update",
      "url": "https://www.chillicothegazette.com/press-release/story/45465/aspire-biopharma-provides-q3-2025-business-update/",
      "time_published": "20251205T200908",
      "authors": [
        "Aspire Biopharma Holdings",
        "Inc."
      ],
      "summary": "Aspire Biopharma (Nasdaq:ASBP) released its Q3 2025 business update, highlighting significant progress in its sublingual drug delivery technology. Key achievements include expanding its scientific team, submitting a Pre-IND meeting request to the FDA for its sublingual aspirin, actively pursuing licensing opportunities at CPHI Frankfurt, and increasing production capacity for its BUZZ BOMB\u2122 caffeine product. The company also reported positive bioavailability trial data for its sublingual aspirin and aims for a New Drug Application submission in H1 2026.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1112550",
      "source": "Chillicothe Gazette",
      "category_within_source": "General",
      "source_domain": "Chillicothe Gazette",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.945751"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.801551"
        },
        {
          "topic": "finance",
          "relevance_score": "0.612812"
        },
        {
          "topic": "technology",
          "relevance_score": "0.634051"
        }
      ],
      "overall_sentiment_score": 0.514687,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.513472",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Aspire Biopharma (Nasdaq: ASBP) targets H1 2026 NDA after fast-acting aspirin data",
      "url": "https://www.stocktitan.net/news/ASBP/aspire-biopharma-provides-q3-2025-business-g1odp13evgml.html",
      "time_published": "20251205T051232",
      "authors": [
        "NULL"
      ],
      "summary": "Aspire Biopharma (Nasdaq: ASBP) provided a Q3 2025 business update, highlighting positive bioavailability data for its sublingual high-dose aspirin, showing platelet inhibition significantly faster than chewed aspirin. The company also announced a positive FDA response to its Pre-IND request, filed an omnibus patent application for its delivery platform, and increased commercial capacity for its BUZZ BOMB\u2122 caffeine product. Aspire aims to submit a New Drug Application (NDA) for its sublingual aspirin program in the first half of 2026.",
      "banner_image": "NULL",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.024301,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "0.303918",
          "ticker_sentiment_score": "0.011354",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Aspire Biopharma (NASDAQ: ASBP) Requests FDA Pre-IND Meeting on Sublingual AMI Aspirin",
      "url": "https://www.stocktitan.net/news/ASBP/aspire-biopharma-submits-pre-ind-meeting-request-and-briefing-ku8k1jkorsbv.html",
      "time_published": "20251204T220956",
      "authors": [
        "NULL"
      ],
      "summary": "Aspire Biopharma (NASDAQ: ASBP) recently announced the submission of a Pre-IND meeting request and brief package to the U.S. FDA on November 3, 2025, for its sublingual aspirin product aimed at treating suspected acute myocardial infarction (heart attack). The company's clinical trial results claim the formulation inhibits platelet aggregation in under two minutes, acting 4\u20135 times faster than chewed aspirin, with higher plasma ASA and reduced serum TxB2 levels reported, and was found to be safe and well-tolerated. Aspire is pursuing a 505(b)(2) regulatory pathway targeting an NDA submission in the first half of 2026.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1112553",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.918266"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.601171"
        }
      ],
      "overall_sentiment_score": 0.210897,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.316885",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.587257",
          "ticker_sentiment_score": "0.110967",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Aspire Biopharma Provides Q3 2025 Business Update",
      "url": "https://www.coshoctontribune.com/press-release/story/29932/aspire-biopharma-provides-q3-2025-business-update/",
      "time_published": "20251204T200922",
      "authors": [
        "Aspire Biopharma Holdings",
        "Inc."
      ],
      "summary": "Aspire Biopharma Holdings, Inc. has provided a business update for Q3 2025, highlighting significant advancements in its sublingual drug delivery technology. Key developments include expanding its scientific team, submitting a Pre-IND meeting request to the FDA for its sublingual aspirin product, and successfully launching its BUZZ BOMB\u2122 caffeine product with increased production capacity. The company anticipates milestones such as a New Drug Application submission for sublingual aspirin in H1 2026 and the initiation of clinical studies for sublingual ED medication.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1112550",
      "source": "Coshocton Tribune",
      "category_within_source": "General",
      "source_domain": "Coshocton Tribune",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.947280"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.802805"
        }
      ],
      "overall_sentiment_score": 0.510965,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.534510",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Aspire Biopharma Provides Q3 2025 Business Update",
      "url": "https://www.norwichbulletin.com/press-release/story/15798/aspire-biopharma-provides-q3-2025-business-update/",
      "time_published": "20251204T200922",
      "authors": [
        "Aspire Biopharma Holdings",
        "Inc."
      ],
      "summary": "Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) has provided a business update for Q3 2025, highlighting significant advancements in its sublingual drug delivery technology. Key achievements include expanding its scientific team, submitting a Pre-IND request to the FDA for its sublingual aspirin, and launching its BUZZ BOMB\u2122 caffeine product with increased production capacity. The company anticipates milestones such as an NDA submission for sublingual aspirin in H1 2026 and the initiation of clinical studies for a sublingual ED medication.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1112550",
      "source": "Norwich Bulletin",
      "category_within_source": "General",
      "source_domain": "Norwich Bulletin",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.947415"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.940278"
        }
      ],
      "overall_sentiment_score": 0.458072,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.499692",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Aspire Biopharma Provides Q3 2025 Business Update",
      "url": "https://www.wric.com/business/press-releases/accesswire/1112550/aspire-biopharma-provides-q3-2025-business-update",
      "time_published": "20251204T090000",
      "authors": [
        "NULL"
      ],
      "summary": "Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) has released its Q3 2025 business update, highlighting significant progress in its sublingual drug delivery technology. Key achievements include expanding its scientific team, submitting a Pre-IND meeting request to the FDA for its lead product candidate (sublingual aspirin), and filing an omnibus patent application. The company also reported successful commercialization efforts for its BUZZ BOMB\u2122 caffeine product and outlined anticipated milestones like an NDA submission for sublingual aspirin in H1 2026.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1112550",
      "source": "WRIC ABC 8News",
      "category_within_source": "General",
      "source_domain": "WRIC ABC 8News",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.926253"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.480834,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.486735",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Aspire Biopharma Provides Q3 2025 Business Update",
      "url": "https://www.azcentral.com/press-release/story/15792/aspire-biopharma-provides-q3-2025-business-update/",
      "time_published": "20251203T210842",
      "authors": [
        "Aspire Biopharma Holdings",
        "Inc."
      ],
      "summary": "Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) has provided a business update for Q3 2025, highlighting expanded scientific team, a positive FDA response regarding its lead product candidate, and participation in CPHI Frankfurt. The company also filed an omnibus patent application, increased production capacity for its BUZZ BOMB\u2122 caffeine product, and published positive data from a sublingual aspirin bioavailability trial. Major upcoming milestones include a targeted NDA submission for sublingual aspirin in H1 2026 and initiation of clinical studies for a sublingual ED medication.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1112550",
      "source": "azcentral.com and The Arizona Republic",
      "category_within_source": "General",
      "source_domain": "azcentral.com and The Arizona Republic",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.949396"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.916072"
        }
      ],
      "overall_sentiment_score": 0.481337,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.491149",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Aspire Biopharma Provides Q3 2025 Business Update",
      "url": "https://www.cincinnati.com/press-release/story/15698/aspire-biopharma-provides-q3-2025-business-update/",
      "time_published": "20251202T200913",
      "authors": [
        "Aspire Biopharma Holdings",
        "Inc."
      ],
      "summary": "Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) has provided a business update for Q3 2025, highlighting significant advancements in its sublingual drug delivery technology. Key developments include expanding its scientific team, submitting a Pre-IND meeting request to the FDA for its lead product candidate (a fast-acting, high-dose sublingual aspirin), and filing an omnibus patent application for its technology. The company also reported positive final data from a bioavailability trial for its sublingual aspirin, which showed faster platelet aggregation inhibition than chewed aspirin, and successfully launched its BUZZ BOMB\u2122 caffeine product with increased production capacity and positive consumer feedback.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1112550",
      "source": "Cincinnati Enquirer",
      "category_within_source": "General",
      "source_domain": "Cincinnati Enquirer",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.938311"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.848745"
        }
      ],
      "overall_sentiment_score": 0.494544,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.457698",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)",
      "url": "https://www.abc4.com/business/press-releases/accesswire/1112553/aspire-biopharma-submits-pre-ind-meeting-request-and-briefing-package-to-u-s-fda-for-sublingual-aspirin-product-for-treatment-of-suspected-acute-myocardial-infarction-heart-attack",
      "time_published": "20251202T090000",
      "authors": [],
      "summary": "Aspire Biopharma has submitted a Pre-IND meeting request and briefing package to the U.S. FDA for its sublingual aspirin product designed for suspected acute myocardial infarction (heart attack) treatment. Clinical trials have demonstrated that this fast-acting formulation inhibits platelet aggregation significantly faster than chewed aspirin, potentially preserving heart muscle. The company aims for FDA approval via the expedited 505(b)(2) regulatory pathway, leveraging its versatile sublingual delivery platform.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1112553",
      "source": "ABC4 Utah",
      "category_within_source": "General",
      "source_domain": "ABC4 Utah",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.409883,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.426429",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member",
      "url": "https://www.wric.com/business/press-releases/accesswire/1112311/aspire-biopharma-welcomes-dr-mark-j-jaroszeski-as-new-scientific-team-member",
      "time_published": "20251201T051232",
      "authors": [
        "NULL"
      ],
      "summary": "Aspire BioPharma Holdings, Inc. has announced the addition of Dr. Mark J. Jaroszeski, a tenured professor and leading innovator in DNA/drug delivery technologies, to its scientific team. Dr. Jaroszeski's extensive experience, including 34 U.S. patents and pioneering work in in vivo electroporation, is expected to be instrumental in advancing Aspire's proprietary sublingual delivery technology and expanding its pipeline. He will play a critical role in optimizing the platform for a broader range of generic medicines.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1112311",
      "source": "WRIC ABC 8News",
      "category_within_source": "General",
      "source_domain": "WRIC ABC 8News",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.462948,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.484389",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Why LightPath Technologies Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket",
      "url": "https://www.benzinga.com/news/25/11/48796517/why-lightpath-technologies-shares-are-trading-higher-by-7-here-are-20-stocks-moving-premarket",
      "time_published": "20251126T190915",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "LightPath Technologies (NASDAQ: LPTH) shares surged in pre-market trading after the company reported better-than-expected first-quarter financial results, including a smaller loss per share and higher revenue than anticipated. This article also lists other stocks experiencing significant pre-market movements, both gainers and losers, along with brief explanations for their fluctuations.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/07/24/article-header-background-image.png?quality=85&auto=webp&width=1300",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "Benzinga",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.921330"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.843487"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.607834"
        },
        {
          "topic": "technology",
          "relevance_score": "0.646436"
        }
      ],
      "overall_sentiment_score": -0.393329,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "0.836843",
          "ticker_sentiment_score": "-0.398438",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member",
      "url": "https://www.lenconnect.com/press-release/story/399296/aspire-biopharma-welcomes-dr-mark-j-jaroszeski-as-new-scientific-team-member/",
      "time_published": "20251125T200913",
      "authors": [
        "Aspire Biopharma Holdings",
        "Inc."
      ],
      "summary": "Aspire BioPharma (NASDAQ:ASBP) has appointed Dr. Mark J. Jaroszeski, a globally recognized expert in DNA and drug delivery, to its scientific team. Dr. Jaroszeski, a tenured professor at the University of South Florida, brings extensive experience crucial for advancing Aspire's sublingual delivery technology. His involvement is expected to significantly contribute to expanding the company's pipeline and applying its delivery platform to a wider range of generic medicines.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1112311",
      "source": "lenconnect.com",
      "category_within_source": "General",
      "source_domain": "lenconnect.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.004456,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "0.310810",
          "ticker_sentiment_score": "0.022985",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member",
      "url": "https://www.abc4.com/business/press-releases/accesswire/1112311/aspire-biopharma-welcomes-dr-mark-j-jaroszeski-as-new-scientific-team-member",
      "time_published": "20251124T230945",
      "authors": [
        "NULL"
      ],
      "summary": "Aspire BioPharma Holdings, Inc. (NASDAQ:ASBP) has appointed Dr. Mark J. Jaroszeski, PhD, a tenured professor in the Department of Medical Engineering at the University of South Florida, to its scientific team. Dr. Jaroszeski is globally recognized for his pioneering work in DNA and drug delivery and his expertise is expected to be instrumental in advancing Aspire's proprietary sublingual delivery technology. This strategic addition aims to strengthen the company's innovation in medical delivery systems and expand its pipeline of generic medicines.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1112311",
      "source": "ABC4 Utah",
      "category_within_source": "General",
      "source_domain": "ABC4 Utah",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.453086,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.458254",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin",
      "url": "https://www.cincinnati.com/press-release/story/12191/aspire-biopharma-engages-with-global-pharmaceutical-leaders-at-cphi-frankfurt-to-advance-partnership-discussions-for-its-sublingual-high-dose-aspirin/",
      "time_published": "20251123T200913",
      "authors": [
        "Aspire Biopharma Holdings",
        "Inc."
      ],
      "summary": "Aspire Biopharma successfully participated in CPHI Frankfurt, engaging in numerous strategic discussions with global pharmaceutical companies regarding its novel sublingual high-dose aspirin. The company's management held 16 formal meetings with major industry players like Bayer, Abiogan, and Deva Holdings, focusing on technical collaboration and licensing opportunities. This interest stems from positive investigational study results showing the sublingual aspirin's higher and more rapid plasma concentrations, crucial for treating suspected acute myocardial infarction.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1097577",
      "source": "Cincinnati Enquirer",
      "category_within_source": "General",
      "source_domain": "Cincinnati Enquirer",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.466448,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.481658",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin",
      "url": "https://www.floridatoday.com/press-release/story/55070/aspire-biopharma-engages-with-global-pharmaceutical-leaders-at-cphi-frankfurt-to-advance-partnership-discussions-for-its-sublingual-high-dose-aspirin/",
      "time_published": "20251123T200913",
      "authors": [
        "Aspire Biopharma Holdings",
        "Inc."
      ],
      "summary": "Aspire Biopharma successfully participated in CPHI Frankfurt, the world's largest pharmaceutical event, to discuss partnerships for its novel sublingual high-dose aspirin. The company held numerous strategic meetings with major industry players like Bayer, showcasing compelling clinical data that demonstrates its formulation's higher and more rapid absorption of acetylsalicylic acid compared to chewed aspirin. This engagement is a critical step towards establishing strategic partnerships to bring their innovative product, which has potential for treating acute myocardial infarction, to the global market.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1097577",
      "source": "Florida Today",
      "category_within_source": "General",
      "source_domain": "Florida Today",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.904718"
        },
        {
          "topic": "finance",
          "relevance_score": "0.640446"
        }
      ],
      "overall_sentiment_score": 0.412421,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.436173",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Aspire Biopharma Enters New $100M ELOC Agreement",
      "url": "https://www.tipranks.com/news/company-announcements/aspire-biopharma-enters-new-100m-eloc-agreement",
      "time_published": "20251117T051232",
      "authors": [
        "TipRanks Auto-Generated Newsdesk"
      ],
      "summary": "Aspire Biopharma Holdings (ASBP) has announced a new Equity Line of Credit (ELOC) Agreement with Arena Business Solutions Global SPC II, Ltd. This agreement, dated November 11, 2025, allows Aspire to sell up to $100 million in common stock to Arena. Concurrently, the biopharmaceutical company terminated its previous ELOC agreement from February 2025 with Arena.",
      "banner_image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1306769920-750x406.jpg",
      "source": "TipRanks",
      "category_within_source": "General",
      "source_domain": "TipRanks",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.930597"
        },
        {
          "topic": "finance",
          "relevance_score": "0.819605"
        }
      ],
      "overall_sentiment_score": 0.040853,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.309144",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "WBD",
          "relevance_score": "0.647651",
          "ticker_sentiment_score": "-0.319491",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Why Is Aspire Biopharma Stock (ASBP) Up Today?",
      "url": "https://www.msn.com/en-us/money/topstocks/why-is-aspire-biopharma-stock-asbp-up-today/ar-AA1QsihO",
      "time_published": "20251116T210925",
      "authors": [],
      "summary": "The article title asks why Aspire Biopharma (ASBP) stock is up today, but the content provided is \"MSN\", which offers no information to answer the question. Therefore, no details about the stock's performance or underlying reasons are available.",
      "banner_image": null,
      "source": "MSN",
      "category_within_source": "General",
      "source_domain": "MSN",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.902370"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.731230"
        }
      ],
      "overall_sentiment_score": 0.522224,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.505486",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Aspire Biopharma Approves Key Proposals at Special Meeting",
      "url": "https://www.tipranks.com/news/company-announcements/aspire-biopharma-approves-key-proposals-at-special-meeting",
      "time_published": "20251108T051232",
      "authors": [
        "NULL"
      ],
      "summary": "Aspire Biopharma Holdings' stockholders approved two key proposals at a Special Meeting held on November 4, 2025. These proposals include granting the board discretionary authority to effect a reverse stock split of common stock within one year and approving the issuance of over 19.99% of outstanding shares upon the exercise of Convertible Promissory Notes, adhering to Nasdaq rules. The company, operating in the biopharmaceutical industry, focuses on developing innovative therapies.",
      "banner_image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_296599349-750x406.jpg",
      "source": "TipRanks",
      "category_within_source": "General",
      "source_domain": "TipRanks",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.938134"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.813930"
        }
      ],
      "overall_sentiment_score": 0.145821,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.148348",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Aspire Biopharma Holdings, Inc. SEC 10-Q Report",
      "url": "https://www.tradingview.com/news/tradingview:b03a5d4f96b7e:0-aspire-biopharma-holdings-inc-sec-10-q-report/",
      "time_published": "20251107T135353",
      "authors": [],
      "summary": "Aspire Biopharma Holdings, Inc. has released its Form 10-Q report for Q2 2025, detailing a significant increase in operating expenses and net loss compared to the previous year. The company is actively developing a high-dose sublingual aspirin product, 'Instaprin,' with clinical trial results expected soon, and also a sublingual melatonin sleep-aid. Aspire plans to submit an NDA for its aspirin product and is exploring an OTC FDA Monograph permit for expedited market entry.",
      "banner_image": null,
      "source": "TradingView",
      "category_within_source": "General",
      "source_domain": "TradingView",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.932514"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.822159"
        }
      ],
      "overall_sentiment_score": -0.387016,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.403234",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin",
      "url": "https://www.wjtv.com/business/press-releases/accesswire/1097577/aspire-biopharma-engages-with-global-pharmaceutical-leaders-at-cphi-frankfurt-to-advance-partnership-discussions-for-its-sublingual-high-dose-aspirin",
      "time_published": "20251106T090000",
      "authors": [],
      "summary": "Aspire Biopharma successfully participated in CPHI Frankfurt, engaging in strategic discussions with global pharmaceutical companies regarding its novel sublingual high-dose aspirin. The company's lead product candidate showed promising results in an investigational study, demonstrating higher and more rapid mean plasma concentrations of acetylsalicylic acid compared to chewed aspirin. Aspire Biopharma is now focused on building partnerships to accelerate the development and commercialization of its drug-delivery platform.",
      "banner_image": null,
      "source": "WJTV",
      "category_within_source": "General",
      "source_domain": "WJTV",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.422173,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.428808",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Aspire Biopharma faces potential Nasdaq delisting after compliance shortfall By Investing.com - Investing.com Canada",
      "url": "https://ca.investing.com/news/sec-filings/aspire-biopharma-faces-potential-nasdaq-delisting-after-compliance-shortfall-93CH-4253874",
      "time_published": "20251018T002051",
      "authors": [
        "Investing.com"
      ],
      "summary": "The article reports that Aspire Biopharma is facing a potential Nasdaq delisting. This situation has arisen due to a compliance shortfall, indicating issues with meeting Nasdaq's listing requirements.",
      "banner_image": null,
      "source": "Investing.com Canada",
      "category_within_source": "General",
      "source_domain": "Investing.com Canada",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.723998"
        },
        {
          "topic": "finance",
          "relevance_score": "0.506442"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.543452"
        }
      ],
      "overall_sentiment_score": 0.03106,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "0.325708",
          "ticker_sentiment_score": "0.008253",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Aspire Biopharma Faces Nasdaq Delisting Notice",
      "url": "https://www.tipranks.com/news/company-announcements/aspire-biopharma-faces-nasdaq-delisting-notice",
      "time_published": "20251017T215453",
      "authors": [
        "TipRanks Auto-Generated Newsdesk"
      ],
      "summary": "Aspire Biopharma Holdings received a Nasdaq noncompliance notice on April 16, 2025, due to persistent market value and bid price deficiencies. Failing to regain compliance within 180 days, the company now faces potential delisting and has requested a hearing to present a compliance plan.",
      "banner_image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_2068435553-750x406.jpg",
      "source": "TipRanks",
      "category_within_source": "General",
      "source_domain": "TipRanks",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.922847"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.800404"
        }
      ],
      "overall_sentiment_score": 0.036659,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "0.332986",
          "ticker_sentiment_score": "0.005212",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Aspire Biopharma Holdings, Inc. Announces Filing of Omnibus Patent Application for Its Innovative Sublingual Drug Delivery Platform",
      "url": "https://finance.yahoo.com/news/aspire-biopharma-holdings-inc-announces-123000368.html",
      "time_published": "20251006T123000",
      "authors": [],
      "summary": "Aspire Biopharma Holdings, Inc. has filed an omnibus patent application for its sublingual drug delivery technology, aiming to enhance the pharmacokinetic performance of Active Pharmaceutical Ingredients (APIs). This application seeks broad patent protection for the company's advanced system across various drug classes and substances. The technology is designed for rapid absorption, faster onset of action, and reduced gastrointestinal issues, with interim CEO Kraig Higginson emphasizing its potential to transform sublingual drug delivery and improve patient outcomes.",
      "banner_image": null,
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.937208"
        },
        {
          "topic": "technology",
          "relevance_score": "0.749918"
        }
      ],
      "overall_sentiment_score": 0.489326,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.457998",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Breakthrough 2-Minute Heart Attack Treatment: Aspire's Sublingual Aspirin Beats Standard Tablets in Clinical Tests",
      "url": "https://www.stocktitan.net/news/ASBP/aspire-biopharma-announces-milestone-roadmap-targeting-h2-2025-fda-kq0qqprsokmh.html",
      "time_published": "20251001T190939",
      "authors": [
        "NULL"
      ],
      "summary": "Aspire Biopharma has announced its pipeline roadmap through 2026, focusing on its patent-pending sublingual drug delivery technology. Their lead program, a sublingual high-dose aspirin, showed faster absorption and better bioavailability than traditional tablets in clinical tests, targeting an H2 2025 FDA submission. The company's strategy involves reformulating approved drugs for multi-billion-dollar markets, including needle-free semaglutide and a rapid-acting ED medication, both slated for Phase 1 studies in 2026.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1080343",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.913416"
        }
      ],
      "overall_sentiment_score": 0.452505,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.450206",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)",
      "url": "https://www.democratandchronicle.com/press-release/story/93170/aspire-biopharma-announces-breakthrough-final-results-from-clinical-trial-of-investigational-new-sublingual-aspirin-product-for-treatment-of-suspected-acute-myocardial-infarction-heart-attack/",
      "time_published": "20250903T220837",
      "authors": [
        "writer"
      ],
      "summary": "Aspire Biopharma has announced positive final results from its clinical trial of a new sublingual aspirin product for heart attack treatment. The trial showed that their sublingual formulation rapidly inhibited serum thromboxane B2 (TxB2)\u2014a biomarker for platelet aggregation\u2014within two minutes, approximately twice as fast as chewed aspirin tablets. This rapid action could be critical during heart attacks, offering a potential life-saving treatment that Aspire plans to submit for accelerated FDA approval in Q3 2025.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1068032",
      "source": "Democrat and Chronicle",
      "category_within_source": "General",
      "source_domain": "Democrat and Chronicle",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.838917,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.831011",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Breakthrough Heart Attack Treatment: Sublingual Aspirin Shows Superior Results in Aspire Biopharma Trial",
      "url": "https://www.stocktitan.net/news/ASBP/aspire-biopharma-announces-positive-top-line-results-from-clinical-99lu0y7r5eu4.html",
      "time_published": "20250818T230914",
      "authors": [],
      "summary": "Aspire Biopharma (NASDAQ:ASBP) announced positive top-line results from a clinical trial demonstrating that its investigational new sublingual aspirin product achieved higher and faster plasma concentrations of acetylsalicylic acid compared to standard chewed aspirin for suspected acute myocardial infarction. This sublingual formulation offers rapid absorption and reduced GI irritation, potentially saving lives as AMI affects millions annually. Aspire plans to discuss these results with the FDA for a potential accelerated approval pathway.",
      "banner_image": "https://app.accessnewswire.com/imagelibrary/a26b849a-1c04-4741-a68d-cefb3fc40212/1061839/image.png",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.935559"
        },
        {
          "topic": "finance",
          "relevance_score": "0.738572"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.639517"
        }
      ],
      "overall_sentiment_score": 0.413757,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.427327",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Aspire Biopharma\u2019s BUZZ BOMB Shows Promising Initial Feedback",
      "url": "https://finance.yahoo.com/news/aspire-biopharma-buzz-bomb-shows-162247707.html",
      "time_published": "20250725T162247",
      "authors": [
        "Maham Fatima"
      ],
      "summary": "Aspire Biopharma announced positive initial consumer feedback for its new sublingual pre-workout supplement, BUZZ BOMB, which uses nanotechnology for rapid caffeine delivery. The product contains 50mg of caffeine and aims to provide sustained energy and mental focus for athletes. BUZZ BOMB is soft-launched and will be available in 30-unit packs across four flavors.",
      "banner_image": null,
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.917633"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.737119"
        },
        {
          "topic": "retail_wholesale",
          "relevance_score": "0.643235"
        }
      ],
      "overall_sentiment_score": 0.536354,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.517212",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement",
      "url": "https://finance.yahoo.com/news/aspire-biopharma-holdings-inc-announces-123000575.html",
      "time_published": "20250709T200908",
      "authors": [
        "NULL"
      ],
      "summary": "Aspire Biopharma Holdings, Inc. announced positive initial consumer feedback for its new sublingual pre-workout supplement, BUZZ BOMB\u2122, which features 50mg of caffeine and a patent-pending fast-acting sublingual nano technology. The product, available in four flavors, aims to rapidly deliver energy and mental focus to athletes and fitness enthusiasts. Aspire plans to officially launch BUZZ BOMB\u2122 at the FITCON and Fit Expo conventions in August, targeting the multi-billion-dollar pre-workout market.",
      "banner_image": "https://s.yimg.com/ny/api/res/1.2/5g5dATerBQM778kW11RoTg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE4ODtoPTQ4/https://s.yimg.com/os/creatr-uploaded-images/2025-01/88364d00-d410-11ef-beff-b428e6fcfd64",
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.946885"
        }
      ],
      "overall_sentiment_score": 0.041668,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "0.331311",
          "ticker_sentiment_score": "0.019678",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation",
      "url": "https://finance.yahoo.com/news/aspire-biopharma-holdings-inc-announces-123000473.html",
      "time_published": "20250520T200902",
      "authors": [],
      "summary": "Aspire Biopharma Holdings has announced the dosing of the first patient in its Phase 1 clinical trial for an oral transmucosal fast-acting high-dose aspirin formulation. This trial aims to evaluate the safety, pharmacokinetics, and pharmacodynamics of its sublingual aspirin powder and granules. Topline data is expected in early Q3 2025, with potential to support accelerated FDA approval.",
      "banner_image": "https://s.yimg.com/ny/api/res/1.2/uUUnXAogzjeHGDG0y95TWw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE4ODtoPTQ4O2NmPXdlYnA-/https://s.yimg.com/os/creatr-uploaded-images/2025-01/88364d00-d410-11ef-beff-b428e6fcfd64",
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.920899"
        }
      ],
      "overall_sentiment_score": 0.499178,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ASBP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.458190",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    }
  ]
}